Shionogi Receives Approvals of Pediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic, "Finibax® 0.25g/0.5g for Intravenous Drip Infusion" and "Finibax® 0.25g Kit for Intravenous Drip Infusion"

Osaka, Japan, May 25, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that it had received approvals of pediatric use and an additional indication for purulent meningitis of a carbapenem-type antibiotic, "Finibax® 0.25g/0.5g for Intravenous Drip Infusion" and "Finibax® 0.25g Kit for Intravenous Drip Infusion" (generic name: doripenem hydrate) in Japan.

Finibax® is a carbapenem-type antibiotic discovered and developed by Shionogi with a strong and broad antibacterial spectrum, covering gram-positive to gram-negative bacteria as well as aerobic to anaerobic bacteria. Since this drug has strong antibacterial activity against *Pseudomonas aeruginosa*, which is often a causal agent in serious and intractable infections, it has been prescribed with high frequency. In Japan, Shionogi has launched "Finibax® 0.5g for Intravenous Drip Infusion" since November, 2011 after receiving an approval of maximum daily dose of 3g in addition to a vial product, "Finibax® 0.25g for Intravenous Drip Infusion" and a combined product of the injectable antibiotic and its diluting agent, "Finibax® 0.25g Kit for Intravenous Drip Infusion" which is enhanced convenience, aseptic condition and assuredness in preparation.

With these approvals of pediatric use and an additional indication of purulent meningitis, Finibax® is expected the further contribution to medical needs.
Shionogi, as a leading company in the field of anti-infectives**,** continues to be dedicated to research and development and medical educational to globally improve to the treatment of infectious diseases, especially those of bacterial and viral origin.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing

products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885
Fax: +81-6-6229-9596